Shots Fight Cancer-Linked Virus 8 Years

A vaccine appears to protect against human papillomavirus (HPV) for 8 years, a new study finds. Human papillomavirus causes most cases of cervical cancer. This was a long-term follow-up to an earlier study. In the original study, more than 1,700 boys and girls were randomly assigned to receive the vaccine or placebo shots. Those who received the placebo were given the actual vaccine 2½ years later. Researchers called this the catch-up group. In the first group, the average child was 12 when vaccinated. In the catch-up group, the average age was 15. Each person received 3 doses. Researchers were able to keep track of more than 1,600 of the original study group. This included 1,100 from the first vaccination group. After up to 8 years (average 6.8), the vast majority of this group had blood antibodies against HPV.

Content restricted. Requires subscription

Many Get Cancer Screening at Advanced Ages

Many older adults who are unlikely to live more than 10 years still are given routine screening tests for cancer, new studies show. But those tests are unlikely to help them and may have risks, the authors say. One study used 10 years of data from a U.S. government health survey. It included 27,000 men and women ages 65 and older. Based on their health history, the authors estimated their risk of dying in less than 10 years. Among men at the highest risk of near-term death, 31% to 55% received screening tests for various types of cancer. A second story focused on screening for colon cancer in adults 65 or older. It was based on Medicare records. About 1 in 5 of those who had a colonoscopy that found no problems ended up having another colonoscopy 5 years later. This test is recommended every 10 years.

Content restricted. Requires subscription